The contract biomanufacturing global market is expected to grow at double digit CAGR to reach $36.6 billion by 2025
Biomanufacturing is a widely used term to describe manufacture of biologic molecules for various stages of drug development right from pre-clinical stage to commercial supply. The biologic drug manufacturing is a complex process involving huge capital and sound technical expertise. Many large and small pharmaceutical companies are turning to outsourcing the drug manufacture process to reduce capital investments on capacities and focus more on their core competencies. Contract manufacturing organizations, particularly for R&D and clinical trials, are making product manufacture, more efficient and often less costly.
In addition to that, the use of single-use bioreactors is effectively reducing the manufacture facility cost. This option is more viable for smaller and low-funded companies for their in-house candidate product manufacturing needs, whereby, the companies can avoid $50-$150 million facility costs for construction of fixed, dedicated stainless steel bioreactor-based bioprocessing systems and outsource their manufacturing requirements to CMOs which use single-use facilities which typically cost $25-$40 million for commercial manufacture.
There is a continued growth of biopharmaceutical market which is expected to nearly double in next 10 years. This will be a result of continued new product approvals, expansion of indications for current products which include less-developed countries becoming more affluent and increased drug demand of the aging population in the U.S. and other major pharmaceutical markets. Aging populations are at a high risk of developing chronic diseases such as cancer and arthritis and these diseases are being precisely targeted using biopharmaceuticals.
Many blockbuster drugs losing their exclusivity are also giving room for many biosimilar (and bio-betters) companies to enter into the world's biopharmaceuticals market subsequently attracting many CROs, CDMOs, and CMOs to enter into the picture.
Contract manufacturing market was estimated region wise with segmental revenues for various end user groups such as diagnostics, research reagents and therapeutics. Total available manufacturing capacity was estimated with distinction between GMP vs. non-GMP, in-house vs. CMOs and clinical vs. commercial contract manufacturing. Key developments such as collaborations, capacity expansions and acquisitions were reported and analyzed.
Key Topics Covered:
1 Biologics Contract Manufacturing Global Market 1.1 Executive Summary
2 Market Analysis 2.1 Factors Influencing Market 2.1.1 Drivers and Opportunities 126.96.36.199 Globalization of Outsourcing for Biomanufacturing 188.8.131.52 Increased Funding from Private Investors and Government for Development of Cmos 184.108.40.206 Emergence of Single Use Bioreactors 220.127.116.11 Increasing Biologics Approvals in the Past Year 18.104.22.168 Successful Collaboration and Low Cost for Outsourcing 2.1.2 Restraints and Threats 22.214.171.124 High Requirement for Capital Investments Restraining Many Cmos to Enter the Biologics Space 126.96.36.199 Risk of Product Contamination & Maintaining High Productivity 188.8.131.52 Entry of Large Pharmaceutical Company With Exess Capacity Into the Cmo Market 184.108.40.206 Stringent Regulations and Mandatory Requirement of Cgmp Certifications
3 Contract Biomanufacturing Services 3.1.1 Introduction 3.2 Contract Biomanufacturing, by Process 3.2.1 Biomanufacturing by Mammalian Cell Culture 3.2.2 Biomanufacturing by Microbial Cell Culture 3.2.3 Biomanufacturing by Other Cell Culture 3.3 Contract Biomanufacturing Global Market, by End Users 3.3.1 Contract Biomanufacturing of Diagnostics 3.3.2 Contract Biomanufacturing of Research Reagents 3.3.3 Contract Biomanufacturing of Therapeutics 3.4 Contract Biomanufacturing Global Market, by Region 3.5 Competitive Landscape 3.5.1 Capacity Comparison 3.5.2 Contract Biomanufacturing Global Market Share, by Leading Players 3.6 Company Developments 3.6.1 Merger and Acquisition by Cmos 3.6.2 Collaborations 3.6.3 Capacity Expansions
4 Company Profiles 4.1 Abzena Plc 4.2 Albany Molecular Research Inc 4.3 Asahi Glass Co. Ltd. 4.4 Boehringer Ingelheim 4.5 Catalent Inc. 4.6 Charles River Laboratories 4.7 Fujifilm Holdings Corporation 4.8 Horizon Discovery Group, Plc 4.9 Innovent Biologics 4.10 Jhl Biotech Inc. 4.11 Lonza Group 4.12 Merck Kgaa 4.13 Patheon N.V. 4.14 Proteogenix 4.15 Rentschler Biotechnologie Gmbh 4.16 Selexis Sa 4.17 Syngene International 4.18 Wuxi Apptec